Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on September 11, 2020, with the latest event date reported as September 15, 2020. The filing primarily addresses changes in corporate governance and updates on the regulatory status of the Company's lead drug candidate, MAT9001.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The only financial-related details provided pertain to specific equity compensation arrangements for directors:
- Adam Stern (Outgoing Director): To receive 100,000 shares of restricted stock and an extension of vesting terms for outstanding options and warrants under a new one-year consulting agreement.
- Natasha Giordano (New Director): Awarded 287,917 stock options exercisable at $0.693 per share, vesting monthly over 36 months.
Material Changes
Board of Directors Changes
- Departure: Adam Stern will not stand for re-election at the November 2, 2020 Annual Meeting due to other commitments. His term expires at that meeting.
- Appointment: Natasha Giordano was appointed as a director, effective September 14, 2020. She will also serve on the Audit Committee.
Regulatory Milestone
- The Company held an End of Phase 2 meeting with the U.S. FDA regarding MAT9001 for the treatment of severe hypertriglyceridemia (SHTG).
- The FDA and Company are aligned on the Phase 3 development program and registration pathway.
Guidance, Outlook, and Management Commentary
Management confirmed that the Company remains on track to initiate its Phase 3 program for MAT9001 in the first half of 2021. Key outcomes from the FDA meeting include:
- Agreement on a single 12-week study to support efficacy in SHTG for a New Drug Application (NDA).
- FDA provided flexibility regarding the totality of patient safety data required for NDA submission.
- The Company is evaluating methods to meet these requirements while potentially generating data to differentiate MAT9001 from other prescription omega-3 drugs.
Investor Verification Checklist
- Verify the terms of the consulting agreement with Adam Stern, specifically the 100,000 restricted shares and stock sale restrictions through August 1, 2021.
- Confirm the vesting schedule and exercise price ($0.693) for the 287,917 options granted to Natasha Giordano.
- Monitor the initiation of the Phase 3 clinical trial for MAT9001, currently targeted for the first half of 2021.
- Review the specific patient safety data requirements agreed upon with the FDA to ensure alignment with the Company's development plan.